LEO Pharma

LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device

Share

Ballerup, DENMARK and Cambridge, MA, USA – December 4, 2019 – LEO Pharma A/S and Portal Instruments today announced a global collaboration and license agreement to develop Portal’s innovative needle-free drug delivery system for use in combination with LEO Pharma’s portfolio of investigational and approved medicines.

Portal Instruments has developed a needle-free jet injector platform to address the increasing needs of patients to self-administer biologics without the need for needles. This simplifies administration, eliminates the need for “sharps containers” in the home, and reduces the time needed to perform self-injections. This technology is particularly timely in light of the increasing use of monoclonal antibodies and therapeutic proteins in drug development. Initially developed by Prof. Ian Hunter’s Group at the Massachusetts Institute of Technology (MIT), the Portal drug administration technology has the potential to transform the way injectable medicines are administered across a wide range of therapeutic indications.

The Portal needle-free system is composed of a re-usable, software-controlled handheld injection device and a proprietary, single-use, pre-filled cartridge. It delivers the medicine through a pressurized liquid jet instead of a needle and has been clinically shown to be less painful and preferred by patients as compared to a standard needle-based injection.1

“LEO Pharma’s novel therapies in the field of medical dermatology combined with Portal’s innovative approach to drug administration offer hope to people living with debilitating skin diseases,” said Christian Antoni, Senior Vice President, Global Development at LEO Pharma. “It is our ambition that this collaboration will lead to new and easier ways for people with skin diseases to administer our treatments on their own in the comfort of their home with a needle-free solution.”

“We are excited at the prospect of working closely with LEO Pharma and support their ambition to empower people with skin diseases with a next-generation drug delivery platform for self-administration,” said Patrick Anquetil, CEO of Portal. “This commercial collaboration gives us the opportunity to lead with innovation in the field of medical dermatology by combining novel medicines with a patient-preferred needle-free drug delivery system.”

[1] Kojic, et al.  An Innovative Needle-free Injection System: Comparison to 1 ml Standard, 1 May 2017, AAPS PharmSciTech (# 2017)

Contacts

Portal Instruments, Inc
Dr. Patrick Anquetil,
Chief Executive Officer
E-mail: media@portalinstruments.com

 
LEO Pharma A/S
Maia Fredtoft Soechting,
Corporate Communications Manager
E-mail: mfddk@leo-pharma.com
Tel: +45 2681 4579

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma A/S

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 76 million patients in 130 countries.

For more information, please visit www.leo-pharma.com.

About Portal Instruments, Inc.

Portal Instruments is a venture-backed medical device company, developing and commercializing a connected, needle-free drug delivery platform to transform the administration of medications for chronic diseases.  Portal aims to improve the patient experience and outcomes through an innovative needle-free injector with connectivity, analytics, and a companion digital experience. Portal partners with pharmaceutical companies to develop unique drug delivery solutions for their therapies. Its first commercial partnership is with Takeda Pharmaceuticals in the field of Inflammatory Bowel Diseases. Portal Instruments’ Quality Management System is ISO 13485 certified.

For more information, please visit www.portalinstruments.com or follow @portalcambridge on Twitter.

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma presents results from study of twice-weekly Enstilar® (calcipotriene and betamethasone dipropionate) Foam for topical use in long-term maintenance treatment of plaque psoriasis12.6.2020 21:20:42 CESTPress release

New results from the PSO-LONG clinical trial are the first to provide long-term maintenance data for plaque psoriasis with a twice-weekly topical treatment with Enstilar®(calcipotriene and betamethasone dipropionate) Foam Plaque psoriasis is a chronic, multifactorial disease affecting nearly 80% of the 125 million people living with psoriasis worldwide(1,2) LEO Pharma is committed to building on its more than 30-year heritage of pursuing innovative products for patients affected by psoriasis and other chronic skin conditions BALLERUP, Denmark, JUNE 12, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today presented results from the Phase 3 PSO-LONG clinical trial. PSO-LONG compared the efficacy and safety of twice-weekly Enstilar® (calcipotriene and betamethasone dipropionate)Foam, versus foam vehicle for long-term (52-week) maintenance treatment for adult patients with plaque psoriasis.(3,4) Results were presented as ePosters online at the American Academy of Dermatolog

Tralokinumab achieves primary and secondary endpoints in three pivotal Phase 3 trials in adult patients with moderate-to-severe atopic dermatitis12.6.2020 21:06:15 CESTPress release

Presented at the AAD VMX 2020, results from ECZTRA 1, 2 and 3 trials confirm tralokinumab met its primary and secondary endpoints and are the first Phase 3 results in atopic dermatitis for an investigational therapy that specifically targets IL-13 Tralokinumab demonstrated statistically significant improvements in outcomes including pruritus (itch) and health-related quality of life measures that are important to patients In ECZTRA 1 and 2, the majority of patients treated with tralokinumab 300 mg every two weeks who achieved a clinical response at week 16, maintained response at week 52 without any use of topical corticosteroids In ECZTRA 3, nine out of 10 patients who achieved clear or almost clear skin with tralokinumab 300 mg in combination with topical corticosteroids at week 16 maintained this response at week 32 when randomized to dosing every two weeks. Similarly, eight out of 10 patients randomized to dosing every four weeks at week 16 maintained clear or almost clear skin at

LEO Pharma announces European Medicines Agency acceptance of marketing authorization application for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis11.6.2020 14:00:00 CESTPress release

BALLERUP, Denmark, JUNE 11, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Medicines Agency (EMA) validated the marketing authorization application (MAA) for tralokinumab, an investigational product for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD). The acceptance of this MAA marks the beginning of the formal review procedure for this potential new treatment by the EMA’s Committee for Medicinal Products for Human Use (CHMP).

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom